Mostrar el registro sencillo del ítem
Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients
dc.contributor.author | Yaribeygi H. | |
dc.contributor.author | Butler A.E. | |
dc.contributor.author | Barreto G.E. | |
dc.contributor.author | Sahebkar A. | |
dc.date.accessioned | 2020-09-02T22:30:36Z | |
dc.date.available | 2020-09-02T22:30:36Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1002/jcp.27278 | |
dc.identifier.citation | 234, 3, 2436-2446 | |
dc.identifier.issn | 00219541 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/6643 | |
dc.description | Many vascular complications are related to exposure of tissues to elevated levels of glucose, a condition that promotes oxidative stress. The primary goal of antidiabetic medication is for normalization of blood glucose. However, antidiabetic medications may have antioxidant effects that go beyond their hypoglycemic influences. Therefore, antidiabetic drugs may be doubly beneficial in preventing diabetic complications. Vascular dysfunction due to uncontrolled diabetes is a serious complication of the disease and one which has a severe impact on quality of life. Readjustment of the oxidative balance in subjects with diabetes, and the positive effects thereof is a topic of intense interest at present. In the current review, we highlight the antioxidant effects of antidiabetic medications which may prevent or delay the onset of vascular dysfunction. © 2018 Wiley Periodicals, Inc. | |
dc.language.iso | en | |
dc.publisher | Wiley-Liss Inc. | |
dc.subject | antidiabetic medications | |
dc.subject | diabetes | |
dc.subject | diabetic nephropathy (DN) | |
dc.subject | oxidative stress | |
dc.subject | vascular dysfunction | |
dc.subject | 2,4 thiazolidinedione derivative | |
dc.subject | antidiabetic agent | |
dc.subject | biguanide derivative | |
dc.subject | dipeptidyl peptidase IV inhibitor | |
dc.subject | glucagon like peptide 1 receptor agonist | |
dc.subject | insulin | |
dc.subject | sodium glucose cotransporter 2 inhibitor | |
dc.subject | sulfonylurea derivative | |
dc.subject | antidiabetic agent | |
dc.subject | antioxidant | |
dc.subject | antioxidant activity | |
dc.subject | diabetic complication | |
dc.subject | diabetic patient | |
dc.subject | drug mechanism | |
dc.subject | human | |
dc.subject | nonhuman | |
dc.subject | oxidative stress | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | vascular disease | |
dc.subject | cardiovascular disease | |
dc.subject | diabetes mellitus | |
dc.subject | diabetic angiopathy | |
dc.subject | drug effect | |
dc.subject | glucose blood level | |
dc.subject | metabolism | |
dc.subject | pathology | |
dc.subject | quality of life | |
dc.subject | Antioxidants | |
dc.subject | Blood Glucose | |
dc.subject | Cardiovascular Diseases | |
dc.subject | Diabetes Mellitus | |
dc.subject | Diabetic Angiopathies | |
dc.subject | Humans | |
dc.subject | Hypoglycemic Agents | |
dc.subject | Oxidative Stress | |
dc.subject | Quality of Life | |
dc.title | Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients | |
dc.type | Review |